Your session is about to expire
← Back to Search
FT-7051 for Prostate Cancer
Study Summary
This trial is testing a new drug, FT-7051, to see if it is safe and effective in treating men with metastatic castration-resistant prostate cancer.
- Metastatic Castration Resistant Prostate Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How has FT-7051 been evaluated for its safety profile?
"FT-7051 has not yet been thoroughly tested, so our team at Power gave it a safety score of 1. This is because Phase 1 trials only provide scant evidence regarding the efficacy and risk profile of this medication."
Is the scope of this clinical trial confined to North America, or is it more expansive?
"Currently, this medical trial is enrolling patients from 8 geographically dispersed locations. These include Saint Louis, New york and Durham with the other 5 located elsewhere. To reduce travel demands for participants it may be beneficial to select a site nearest you if deciding to join in on the study."
Are there any open enrollment opportunities for this research endeavor?
"Correct. Records hosted on clinicaltrials.gov demonstrate that this research is presently enrolling participants, which were initially posted on December 30th 2020 and was last modified on May 12th 2022. A total of 45 patients need to be recruited from 8 separate medical facilities."
What is the cap on enrollment for this research endeavor?
"Forma Therapeutics, Inc. is the sponsor of this trial and requires 45 participants that meet the criteria to complete it. The research will take place in Washington University School of Medicine (St Louis, Missouri) and Icahn School of Medicine at Mt Sinai (New york City)."
Share this study with friends
Copy Link
Messenger